Press Release AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 7 hours ago
Press Release AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD) Aug 11